8-K: Nanophase Technologies Secures $6 Million Financing to Bolster Growth Strategy

Nanophase Technologies has secured $6 million in funding through a convertible preferred stock agreement with Strandler, LLC, an affiliate of its largest shareholder, to support its growth strategy and address recent financial challenges.

Summary

• Nanophase Technologies Corporation has entered into a Securities Purchase Agreement with Strandler, LLC, an affiliate of its largest shareholder, Bradford T. Whitmore.
• Strandler has purchased 15,000 shares of Series X Preferred Stock for a total of $6 million, with each share priced at $400.
• The Series X Preferred Stock is convertible into 1,000 shares of common stock per preferred share, pending shareholder approval to increase the authorized common stock from 60 million to 95 million shares.
• If the company fails to file the amendment to increase authorized shares by August 1, 2024, the preferred stock becomes redeemable at $420 per share.
• The company also amended loan agreements with Strandler and Beachcorp, extending the maturity date of existing loans to October 1, 2025.
• The financing aims to address working capital needs and support the company's growth strategy after a challenging Q4 2023.
• Q4 2023 revenue was approximately $8 million, with a net loss of $2.1 million, while full year 2023 revenue was $37.3 million with a net loss of $4.4 million, 30% of which was due to legal fees.
• The company has over $30 million in completed shipments and confirmed purchase orders and expects a profitable 2024.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While the company secured crucial funding and extended loan maturities, it also acknowledges recent financial underperformance and production challenges. The forward-looking statements are cautiously optimistic, but the risks and uncertainties are also highlighted.

Positives

• The $6 million financing provides crucial working capital to support the company's growth strategy.
• The extension of loan maturities provides financial flexibility and reduces near-term debt pressure.
• The company has a strong product suite and continues to win innovation awards.
• Demand for Solsence products is reported as excellent.
• The company has a significant backlog of over $30 million in completed shipments and confirmed purchase orders.
• Management expects 2024 to be a profitable year with more opportunities for growth.

Negatives

• Q4 2023 financial performance fell short of expectations, resulting in a net loss of $2.1 million.
• The company experienced shortages of critical raw materials in early January, causing production delays.
• The company's full year 2023 net loss was $4.4 million, with legal fees contributing significantly to the loss.
• The company is dependent on a limited number of key customers.

Risks

• The company's ability to convert the preferred stock is contingent on shareholder approval to increase authorized common shares.
• Failure to obtain shareholder approval by August 1, 2024, will trigger a redemption of the preferred stock at $420 per share.
• The company is dependent on a limited number of key customers, and a decision by a customer to cancel a purchase order could have a material impact.
• There is uncertain demand for, and acceptance of, the company's engineered materials, ingredients, and fully formulated products.
• The company's manufacturing capacity and product mix flexibility may be challenged by customer demand.
• The company has limited marketing experience.
• The company is dependent on patents and protection of proprietary information.
• The company may be involved in litigation.
• New government regulations could be costly to comply with.
• The company's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations.

Future Outlook

The company expects 2024 to be a profitable year with more opportunities for growth from a stable platform. They anticipate releasing full 2023 financial results on March 20, 2024, and will host a conference call on March 21, 2024, to discuss these results and 2024 expectations.

Management Comments

• Jess Jankowski, President and CEO, stated that the company's product suite remains strong, they continue to win innovation awards, and demand for their Solsence products is excellent.
• Jankowski noted that November and December financial performance fell short of expectations, leading to a Q4 2023 loss and working capital demands.
• Jankowski explained that the company chose to seek funding to keep its growth strategy on track rather than aggressively cutting expenses.
• Jankowski added that the company is committed to continuing measured cost reductions.
• Jankowski concluded that the financing will help the company operate more efficiently and on a sustainable basis, and that 2024 is expected to be profitable.

Industry Context

This announcement comes as Nanophase, a company focused on mineral-based health care solutions, seeks to capitalize on the growing demand for its products in the beauty and life science sectors. The financing and loan amendments are aimed at addressing short-term financial challenges and positioning the company for future growth in a competitive market.

Comparison to Industry Standards

• While specific financial benchmarks for Nanophase are not provided in the document, the company's revenue and net loss figures can be compared to other small-cap companies in the specialty materials and healthcare sectors.
• The company's reliance on a limited number of key customers is a common risk for smaller companies, and the company's ability to diversify its customer base will be a key factor in its long-term success.
• The company's focus on innovation and patented technologies is a positive sign, but it will need to continue to invest in R&D to maintain its competitive edge.
• The company's ability to manage its working capital and control costs will be critical to achieving profitability in 2024.

Related Party Transactions

• The financing was provided by Strandler, LLC, an affiliate of the company's largest shareholder, Bradford T. Whitmore.
• Loan amendments were made with Strandler, LLC and Beachcorp, LLC, both affiliates of Bradford T. Whitmore.

Stakeholder Impact

• Shareholders will be impacted by the potential dilution of their ownership if the preferred stock is converted to common stock.
• Employees may be impacted by the company's cost reduction efforts.
• Customers may benefit from the company's improved financial stability and ability to meet demand.
• Suppliers may be impacted by the company's financial performance and ability to pay its obligations.
• Creditors will be impacted by the extension of loan maturities.

Next Steps

• The company needs to obtain shareholder approval to increase the authorized number of common shares.
• The company needs to file the Certificate Amendment with the Delaware Secretary of State.
• The company will release full 2023 financial results on March 20, 2024.
• The company will host a conference call on March 21, 2024, to discuss full year 2023 results and 2024 expectations.

Key Dates

Keywords

financing, preferred stock, convertible, working capital, loan amendment, shareholder approval, redemption, revenue, net loss, Solsence, Strandler, Beachcorp